Long-term Results of Coronary Bifurcation Lesion Treatment in Diabetic Patients

The effects of diabetes on patients with coronary artery disease are well-known, and their outcomes after angioplasty are less favorable, with a higher rate of restenosis, recurrent acute myocardial infarction, and stent thrombosis. Despite advances in drug-eluting stents and procedural techniques, the treatment of coronary bifurcation lesions in diabetic patients shows less positive clinical outcomes and a lower procedural success rate compared with the treatment of non-complex coronary lesions.

Resultados a largo plazo del tratamiento de bifurcaciones coronarias en pacientes diabéticos 

The objective of this retrospective, observational, real-world cohort study was to explore the impact of diabetes on the outcomes of coronary transluminal angioplasty (CTA) in bifurcation lesions treated with second-generation stents, as well as to assess the predictors of adverse events during follow-up among diabetic patients.

The primary endpoint (PEP) was the rate of major adverse cardiovascular events (MACE), defined as a combination of all-cause death, acute myocardial infarction, or treated lesion revascularization (TLR).

The analysis included 5537 patients, of which 33% had diabetes. Diabetic patients were older and had a higher prevalence of renal disease (p <0.001), hypertension (p <0.001), dyslipidemia (p <0.001), prior acute myocardial infarction (p = 0.02), previous percutaneous coronary intervention (p <0.001), and previous coronary revascularization surgery (p = 0.006). Angiographically, this patient group showed a higher incidence of diffuse disease (p <0.001) and severe calcification (p <0.001), while there were no differences in left main coronary artery involvement and Medina classification.

Regarding the results, at 21 months, the MACE rate was significantly higher in diabetic patients (17% vs. 9%, p <0.001). The same applied to the incidence of all-cause death (9% vs. 4%, p <0.001), TLR (5% vs. 3%, p = 0.001), acute myocardial infarction (4% vs. 2%, p <0.001), and stent thrombosis (2% vs. 1%, p = 0.007).

Leia também: Escores de qualidade de vida após intervenção percutânea em insuficiência tricúspide: análise do estudo TRILUMINATE.

Regarding the predictors of MACE among diabetics, chronic kidney disease (hazard ratio [HR]: 2.99; confidence interval [CI]: 2.21–4.04, p <0.001), baseline ejection fraction (HR: 0.98; CI: 0.97–0.99, p = 0.04), femoral access (HR: 1.62; CI: 1.23–2.15, p = 0.001), left main coronary artery involvement (HR: 1.44; CI: 1.06–1.94, p = 0.02), main branch diameter (HR: 0.79; CI: 0.66–0.94, p = 0.01), and final kissing balloon (HR: 0.70; CI: 0.52–0.93, p = 0.01) were independent predictors of MACE during follow-up.

Conclusion

In conclusion, diabetic patients undergoing CTA in bifurcation lesions treated with second-generation drug-eluting stents experienced a higher incidence of MACE, all-cause death, TLR, and stent thrombosis compared with non-diabetic patients.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Membro do Conselho Editorial da SOLACI.org.

Título Original: Angioplastia coronaria. Impact of diabetes on long‐term outcomes of bifurcation percutaneous coronary intervention. An analysis from the BIFURCAT registry.

Referência: Francesco Bruno MD et al Catheter Cardiovasc Interv. 2023;1–11. 


Subscreva-se a nossa newsletter semanal

Receba resumos com os últimos artigos científicos

More articles by this author

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...